Immix Biopharma (IMMX) Total Non-Current Liabilities (2020 - 2024)

Immix Biopharma has reported Total Non-Current Liabilities for 5 years, with the latest figure at $9.7 million in Q4 2024.

• Quarterly Total Non-Current Liabilities rose 160.54% year-over-year to $9.7 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $9.7 million (up 160.54% YoY) and the FY2024 annual result came in at $9.7 million, up 160.54% from the prior year.
• Total Non-Current Liabilities improved to $9.7 million in Q4 2024 per IMMX's latest filing, from $7.6 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $9.7 million in Q4 2024 and troughed at -$23.2 million in Q4 2021.
• A 5-year average of $2.0 million and a median of $4.8 million in 2020 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2021 and 2024: Total Non-Current Liabilities slumped 594.4% in 2021, then jumped 160.54% in 2024.
• Over 5 years, Total Non-Current Liabilities stood at $4.7 million in 2020, then plunged by 594.4% to -$23.2 million in 2021, then surged by 107.53% to $1.7 million in 2022, then soared by 112.88% to $3.7 million in 2023, then surged by 160.54% to $9.7 million in 2024.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $9.7 million, $7.6 million, and $4.9 million for Q4 2024, Q3 2024, and Q2 2024 respectively.